Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Virtualisation of the testing environment (VITE)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: European rail initiative
Action type: Research and Innovation actions
Partnership: Shift2Rail (Art-187)
Countries involved: Italy,Italy,Spain,Belgium,Belgium,Czechia
Call: IT virtualization of testing environment (H2020-S2RJU-OC-2015-01-2, 2015)
Start date: 2016-11-01
End date: 2018-12-31
Duration (months): 26.0
Total project cost (EUR): 947756.88
EU funding (EUR): 947756.88
Participants: 12
Project status: CLOSED

The VITE proposal is addressed to the call S2R-OC-IP2-02-2015-IT virtualization of testing environment. The main objective of VITE proposal is to reduce on-site tests for signalling systems leading to reducing overall testing costs. To achieve this main objective the work is organized in two main streams: First, to propose a testing framework by carefully analysing user’s needs and current situation and from there building a process that can be accepted by all railway stakeholders and whose main strength will be to perform as many tests as possible in the lab. An analysis of uncertainties and a simulation of GSMR QoS as well as a proposed methodology for test protocols optimisation will also be addressed. Secondly, to propose a standard architecture for the lab testing including the interface specifications for both the connection between real equipment and the lab tools as for the connection between different labs for remote testing. This architecture will be developed together with some SW tools that will help to automatise lab testing. To validate the test process framework and the lab architecture demonstrations by the participating labs using real track and train data from three of the most significant European countries deploying ETCS (Spain, Italy and Belgium), as well as an assessment by NoBos, DeBos and users from these three countries are also foreseen. Finally VITE has some dissemination and coordination actions to ensure the success and usefulness of the project in particular regarding the coordination with S2R-CFM-IP2-01-2015 and other S2R initiatives. The expected impact of the project is to significantly contribute to the development of a Zero Onsite testing environment. The VITE consortium involves users (RU and IM), independent labs, NoBos/DeBos and engineering and technological companies, all of them leading companies in the railway sector and in particular in signalling and ERTMS. This consortium thus complements the know-how and expertise of the S2R JU members.

Keywords: lab testing,standard architectue,test process framework
Holistic solution to improve animal food production through deconstructing the biomolecular interactions between feed, gut microorganisms and animals in relation to performance parameters (HoloFood)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable and competitive agri-food sector for a safe and healthy diet
Action type: Innovation actions
Countries involved: Germany,Spain,Germany,Spain,Norway,Norway,Poland,Denmark,Denmark,Denmark
Call: Microbiome applications for sustainable food systems (H2020-SFS-2018-1, 2018)
Start date: 2019-01-01
End date: 2023-04-30
Duration (months): 52.0
Total project cost (EUR): 10825325.0
EU funding (EUR): 9863093.0
Participants: 11
Project status: SIGNED

Optimising food production is not only of commercial interest for companies, but with the planet’s population approaching the nine billion mark, also of critical importance for humanity. Animal food production can be optimised by modulating animal-associated microbiomes through the use of feed additives such as prebiotics and probiotics. Previously developed feed additives have not acknowledged the specific means of action of the additives on the microbiome and host organisms, and consequently i) their performance is inconsistent across animals with different genetic background and when grown under different environments, ii) improvement of feed additives is inefficient and costly, and iii) optimal solutions are unlikely to be found without taking a more holistic approach. HoloFood showcases a holistic approach that will improve the efficiency of food production systems by deciphering the molecular and physiological processes triggered by feed additives across animals with different genetic background and grown under different environments. We will use two critically important farmed animal systems as our models -salmon and chicken- and characterise not only their associated microorganisms’ genomes, transcriptomes and metabolomes but also how the microbiome interacts with animals' genomes and transcriptomes within the new holo-omic framework in relation to key performance indices and animal welfare issues. The knowledge generated will be used to optimise feed additive administration strategies of already implemented products by tailoring them to the genetic background and developmental stage of the animals as well as production environment, to improve the quantity, quality and safety of the produced food, as well as sustainability of food production and animal welfare. HoloFood will also serve to raise awareness about the importance of microbiomes in food production, and to establish bridges between companies and academia to foster science-based strategies.

Keywords: hologenomics,symbiosis,multi omics,aquaculture,poultry
MICroACTuators (MICACT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Germany,Spain,Australia,Estonia,Italy,Spain,Italy,Monaco,Switzerland,Sweden,China,New Zealand,France,France,France,Netherlands,United Kingdom,United Kingdom,Canada
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (H2020-MSCA-ITN-2014, 2014)
Start date: 2015-01-01
End date: 2018-12-31
Duration (months): 48.0
Total project cost (EUR): 3300160.68
EU funding (EUR): 3300160.6799999997
Participants: 21
Project status: CLOSED

Electroactive polymers (EAP) consist of materials capable of changing dimensions and/or shape in response to electrical stimuli. Most EAPs are also capable of generating electrical energy in response to applied mechanical forces. These polymeric materials exhibit properties well beyond what conventional metal or plastic-based actuators can offer, including very high mechanical flexibility (can be stretched to twice their initial size), low density, a high grade of processability, scalability, microfabrication readiness and, in most cases, low cost. Micro-EAPs enable a new broad range of applications for which large strains and forces are desirable, and for which built-in intelligence is necessary. The main objective of the project will be the improvement of the career perspectives (in academia and in industry) of young researchers by training them at the forefront of research in the field of smart soft systems made of EAP microactuators for advanced miniaturized devices. The overall objective for the scientific programme is research and development of EAP materials and their integration for industrial applications. Special attention will be devoted to the development of microactuators. The field of smart materials is growing extremely fast. Materials whose stiffness and shape can be controlled, and that are capable of sensing their shape allow new classes of compliant complex systems. Through the MICACT programme, we hope to ensure that European researchers keep their leading role in this blossoming field, and to help them transition to industrial positions.

Keywords: electroactive polymer materials,dielectric elastomers,artificial muscles,smart materials,microactuators
Development of DIALIVE, a novel Liver Dialysis Device for the treatment of patients with Acute on Chronic Liver Failure (ACLF) (ALIVER)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Ireland,Spain,Germany,Spain,Switzerland,Belgium,France,United Kingdom,United Kingdom
Call: New therapies for chronic diseases (H2020-SC1-2016-RTD, 2016)
Start date: 2017-01-01
End date: 2021-01-31
Duration (months): 49.0
Total project cost (EUR): 7846088.75
EU funding (EUR): 6478737.5
Participants: 12
Project status: CLOSED

Liver disease incidence is increasing and about 170K patients die from liver failure each year in Europe. In liver failure, the accumulation of protein bound toxins and increased susceptibility to infection cause multiorgan failure and death. Liver transplantation is the only treatment known to prolong the life but is limited by availability of organs. A clinically efficacious ‘liver dialysis device’ is an unmet clinical need. The ALIVER Consortium has developed and optimised a novel ‘liver dialysis device’, DIALIVE. The DIALIVE device is protected by world-wide patents and is based upon our discovery that (i) albumin, a circulating protein involved in detoxification is reduced irreversibly in function and (ii) endotoxemia contributes to increased risk of infection in liver failure. DIALIVE incorporates albumin removal and replacement and, endotoxin removal and is a TRL5. In animal models of liver failure, DIALIVE was shown to be easy to use, safe, reduced endotoxemia and, improved albumin and immune function and, prolonged survival. The ALIVER Consortium, which is comprised of experts in liver failure, SMEs and charities proposes to perform clinical trials of DIALIVE in patients with acute on chronic liver failure (ACLF). During the grant period a CE-mark will be obtained and the device will progress to a TRL7/8. Consultation with Regulatory bodies confirms that if the trials are successful, a CE-mark is highly likely. Grifols, a large plasma proteins company is a potential licensee of the technology if the studies proposed by the ALIVER Consortium are positive. We plan to take the project through regulatory and ethics approval and perform a study to define its safety in ACLF patients in 18 European hospitals; define health economic benefits to the EU and define a reimbursement strategy. The results will be disseminated widely and results exploited to benefit patients, EU healthcare system, create new jobs and grow healthcare Industry in Europe.

Keywords: liver failure,liver dialysis,liver transplantation,hepatic encephalopathy,hepatorenal syndrome,extracorporeal assist
The first blood test for the early detection and prognosis of Acute Myeloid Leukaemia (SeroStrat)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-05-01
End date: 2018-09-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Acute myeloid leukaemia (AML) accounts for about 25% of all leukaemia in the Western world. Its overall survival rate for 5 years is the lowest of all types of leukaemia (27%): above 60% of AML patients will succumb to the disease. Currently, there is no method for early detection of AML. It is diagnosed based on the presence of blasts in bone marrow samples and must be treated immediately to avoid a near-future death. Due to this late detection, AML treatment is of low effectiveness. The aggressive and often fatal nature of AML makes it a priority for developing early and fast diagnostic and prognostic tools. We have identified a new biomarker for the early detection and prognosis of AML. This biomarker is detected and quantified by our innovative In vitro Diagnostic Test (IVD), named Serostrat, via a fast, cheap and routinely clinical blood analysis. We own the exclusive exploitation rights of SeroStrat. SeroStrat specifically targets the AML biomarker in blood cells, discriminates between AML unfavourable risk patients and AML patients with intermediate risks; is low-invasive and painfulness (only requires a blood sample instead of bone marrow samples); is fast and non-expensive (it can be used routinely in clinics in blood samples analysis by Flow cytometry) and will permit risk groups (persons aged >65), AML new patients, and persons in remission to be monitored easily and accurately for signs of recurrence. We are Leukos Biotech S.L. (Leukos), a Spanish spin-off company founded in 2015 from the prestigious Josep Carreras Leukaemia Research Institute. Our goal is to enter fully into the biopharma sector, which will allow us to move to a business model which will create 50 new jobs and cumulative profits about € 22M by 2024.

Keywords: acute myeloid leukaemia,early detection,biomarker,blood cells,low invasive,blood samples analysis,clinical blood analysis,in vitro diagnostic test
Noč ima svojo moč, European Researchers’ Night (NIGHT) (NOCMOC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European researchers' Night
Action type: Marie Skłodowska-Curie actions
Countries involved: Slovenia
Call: European Researchers' Night (H2020-MSCA-NIGHT-2018, 2018)
Start date: 2018-04-15
End date: 2019-12-14
Duration (months): 20.0
Total project cost (EUR): 175062.5
EU funding (EUR): 175062.5
Participants: 4
Project status: CLOSED

Noč ima svojo moč [The Night has it might] (NOCMOC) [NIGHTMIGHT] project combines a strong awareness campaign embedding a major media campaign and a citizen science project with activities spread all over Slovenia in the two Researchers nights in 2018 and 2019. The core objectives of the NOCMOC project is to raise awareness about the research and its benefits, overcome stereotypes, stimulate curiosity all over Slovenia and excite youngsters to take up the research careers. The awareness campaign will comprise national TV broadcasts, radio broadcasts, press presence and a social media campaign, reaching 100.000 people. Moreover, as a citizen science project, over 500 seeds will be sown all over Slovenia by citizens and will be the basis for collaboratiovecollaborative research: comparing growth, plants characteristics and the physical and chemical properties of Slovenian autochthonous species. We expect seeds to grow throughout the citizens science project in the awareness campaign and to bloom on the Researchers’ night. The NIGHT activities will take place in 17 cities across Slovenia and will bring together 27 research-related institutions to raise awareness about research and innovation, its social and economic benefits as well as its variety of careers. Over 40.000 visitors from different target groups will take part in the NIGHT activities spread all over Slovenia. Activities will combine science festivals on the main square of four cities, research days in 6 primary and secondary schools, over 30 lectures and workshops in public spaces such as libraries, retirement homes and museums, open doors at the research institutions, science centre and cultural institutions.

Keywords: research,innovation,science communications,researchers,participatory event,citizen science project,science careers
Delivering anti-cancer drugs beyond the blood-brain barrier (DOMEUS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-10-01
End date: 2022-09-30
Duration (months): 24.0
Total project cost (EUR): 2995353.5
EU funding (EUR): 2064325.0
Participants: 1
Project status: CLOSED

Founded in 2010, CarThera is a clinical stage company that develops first-in-class medical devices using therapeutic ultrasounds to treat severe brain disorders (Glioblastoma, Brain Metastasis, Alzheimer’s Disease). The company is developing the SonoCloud Device, an implant emitting Low Intensity Pulsed Ultrasound (LIPU) to temporarily open the blood-brain barrier (BBB) on demand, thus enabling the targeted delivery of a higher concentration of therapeutics agents into the brain, up to therapeutic levels (5 to 7 times more than what is possible today). Its LIPU technology can physically increase the permeability of the blood vessels by a mechanism of action that is safe and reversible, allowing molecules to be delivered towards infiltrating brain tumor cells that are normally protected by the BBB. The SonoCloud is offering for the first time in decades a means for clinicians to delay the recurrence and to prevent disease worsening in severe brain disorders like glioblastoma. The efficacy of chemotherapies will be increased. Encouraging results from a first-in-man were recently published in prestigious medical journals. It could also give a second chance to some of the hundreds of drugs against brain tumors that have been abandoned and allow existing, approved oncology drugs to be repurposed for brain tumors, greatly accelerating clinical translation and potential patient benefit. The DOMEUS project is at a pivotal moment, where CarThera is gathering data from an international (American/French), multi-center, pilot clinical study with an enlarged version of the device (SonoCloud-9). The DOMEUS project will allow CarThera to carry out a pivotal phase 2b/3 clinical trial, to industrialize the implant and to prepare for international market introduction in 2023. CarThera will transform from a clinical-stage company to a commercial-stage company, leading the new global market of in ultrasound-mediated drug delivery devices for brain diseases.

Keywords: cancer,oncology,tumor,metastasis,neuro oncology,brain cancer,glioblastoma,blood brain barrier,ultrasound,drug delivery,chemotherapy,medical device,lipu
Insights into Earth’s volatile origin from krypton and xenon isotopic and elemental analyses of meteorites and mantle-derived samples (VolatileOrigin)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Switzerland
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-11-01
End date: 2024-04-01
Duration (months): 24.0
Total project cost (EUR): 203149.44
EU funding (EUR): 203149.44
Participants: 1
Project status: TERMINATED

The presence of volatile elements such as carbon, nitrogen, water, noble gases, on terrestrial planets is a requirement for planet habitability, yet their origin is still highly debated. Noble gases are invaluable tracers of volatile sources due to their inertness, in particular their non-radiogenic isotopes have kept remnant signatures of planetary accretion. Krypton and xenon are mighty tools to distinguish between chondritic and solar volatile sources due to the distinct isotopic compositions of these end-members. However, the heavy noble gas (Kr, Xe) compositions of the Earth’s mantle is poorly determined. Hence, the Earth’s mantle volatile history remains largely unknown. The objectives of this project are to precisely measure the non-radiogenic Kr and Xe isotopes in mantle-derived samples, including mid-ocean ridge basalts and diamonds, and in meteorites of different types in order to better understand Earth’s volatile origin. Determining the compositions of mid-ocean ridge and diamond samples will allow to characterize the extent of mantle Kr and Xe heterogeneities, introduced through progressive atmospheric noble gas recycling via subduction, and, hence to identify the source(s) of these volatiles in the mantle. Precise bulk meteorite data for the non-radiogenic Kr and Xe isotopes are incomplete and will be crucial in our understanding of the measured mantle compositions to fingerprint the volatile sources. This project will use a novel protocol for the specific measurements of these isotopes in mantle-derived samples associated with noble gas mass spectrometry. The MSCA fellowship represents a unique opportunity for me to learn new analytical skills in cosmochemistry, to improve my soft skills and to secure my fruitful reintegration in Europe. I will transfer to the host lab my expertise of mantle geochemistry. On the whole, this project will strengthen my scientific independence, taking me closer to achieve an outstanding academic position in Europe.

Keywords: noble gases,origin of volatiles,earth s mantle,meteorites,krypton,xenon,noble gas mass spectrometry
Enhanced impact of the Factories of the Future PPP through technology transfer and expanded community (FoF-Impact)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Technologies for Factories of the Future
Action type: Coordination and support actions
Partnership: FoF (cPPP)
Countries involved: Germany,Spain,Spain,Italy,Belgium,Greece,Sweden,United Kingdom
Call: Support for the enhancement of the impact of FoF PPP projects (H2020-FoF-2014, 2014)
Start date: 2015-01-01
End date: 2016-12-31
Duration (months): 24.0
Total project cost (EUR): 393559.0
EU funding (EUR): 393559.0
Participants: 9
Project status: CLOSED

The ‘Factories of the Future’ PPP launched in 2008/9 has been a proven success and triggered a unique cooperation between industry, researchers and the European Institutions. The objective of the FoF Impact CSA is to transform the FoF PPP from a research and demonstration programme under FP7 into an innovation programme in Horizon 2020. The FoF-Impact CSA will integrate, in one comprehensive and service-oriented package, a set of tools and measures (guidelines, technology transfer tools and market uptake mechanisms) in support of exploitation of project results generated by the FoF PPP. The FoF-Impact CSA will build upon the existing work, such as the EFFRA Innovation Portal which offers a dynamic community-based environment for sharing and retrieving information about exploitable results. The FoF-Impact CSA will also facilitate collaboration among the main stakeholders which are capable of enhancing the overall impact of the ‘Factories of the Future’ PPP in Horizon 2020 at local and company-level. These actors are: manufacturing industries (large and SMEs), national and regional and other European manufacturing initiatives and programmes (Eureka, Manunet etc); technology transfer organisations and market-uptake experts; industry-focused RTOs and institutes, marketers of exploitable results, potential users of exploitable results, possible investors and business angels. In summary, the FoF Impact CSA will provide tailor-made guidelines and tools (including a FoF-Impact helpdesk) that will service both individual 'Factories of the Future' projects as well as clusters of 'Factories of the Future' projects. The clustering of projects results will be supported both by the existing EFFRA Innovation Portal and through the organisation of specific events, oriented either to technologies, application sectors or specific challenges, and it will thus further stimulate cross-fertilisation and the identification of additional exploitation opportunities.

Keywords: innovation,technology transfer,helpdesk,coaching,clusters,market uptake,exploitable results,factories,manufacturing ppps,application sectors,trade fairs,cross fertilisation